These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3877147)

  • 41. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse.
    Hadjiconstantinou M; Neff NH
    J Neurochem; 1988 Oct; 51(4):1190-6. PubMed ID: 3262149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depletion of striatal dopamine by the N-oxide of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Lau YS; Fung YK; Trobough KL; Cashman JR; Wilson JA
    Neurotoxicology; 1991; 12(2):189-99. PubMed ID: 1956580
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium.
    Vyas I; Heikkila RE; Nicklas WJ
    J Neurochem; 1986 May; 46(5):1501-7. PubMed ID: 3485701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey.
    Jacobowitz DM; Burns RS; Chiueh CC; Kopin IJ
    Psychopharmacol Bull; 1984; 20(3):416-22. PubMed ID: 6332329
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuropharmacological manipulations with MPTP.
    Barnes NJ; Bradbury AJ; Costall B; Domeney AM; Kelly ME; Naylor RJ
    J Neural Transm Suppl; 1986; 20():47-63. PubMed ID: 3091761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK; Sonsalla PK; Heikkila RE
    J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistent depletion of striatal dopamine in mice by 1-methyl-4-(2-thienyl)-1,2,3,6-tetrahydropyridine (MTTP).
    Fuller RW; Robertson DW; Hemrick-Luecke SK
    Biochem Pharmacol; 1986 Jan; 35(2):143-4. PubMed ID: 3484628
    [No Abstract]   [Full Text] [Related]  

  • 49. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones.
    Boyce S; Kelly E; Reavill C; Jenner P; Marsden CD
    Biochem Pharmacol; 1984 Jun; 33(11):1747-52. PubMed ID: 6610420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 1-methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway.
    Bradbury AJ; Costall B; Domeney AM; Jenner P; Kelly ME; Marsden CD; Naylor RJ
    Nature; 1986 Jan 2-8; 319(6048):56-7. PubMed ID: 3484542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
    Fuller RW; Hemrick-Luecke SK
    Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro.
    Chang GD; Ramirez VD
    Brain Res; 1986 Mar; 368(1):134-40. PubMed ID: 3485463
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: an in vivo electrochemical study.
    Gerhardt G; Rose G; Strömberg I; Conboy G; Olson L; Jonsson G; Hoffer B
    J Pharmacol Exp Ther; 1985 Oct; 235(1):259-65. PubMed ID: 2864435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.
    Sonsalla PK; Heikkila RE
    Eur J Pharmacol; 1986 Oct; 129(3):339-45. PubMed ID: 3490988
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of reduced glutathione (GSH) on dopamine (DA) and gamma-aminobutyric acid (GABA) concentration in the mouse brain following intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Smiałek M
    Neuropatol Pol; 1988; 26(3):415-22. PubMed ID: 3267037
    [No Abstract]   [Full Text] [Related]  

  • 57. MPTP causes a non-reversible depression of synaptic transmission in mouse neostriatal brain slice.
    Wilson JA; Wilson JS; Weight FF
    Brain Res; 1986 Mar; 368(2):357-60. PubMed ID: 3008929
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine.
    Tabbal SD; Mink JW; Antenor JA; Carl JL; Moerlein SM; Perlmutter JS
    Neuroscience; 2006 Sep; 141(3):1281-7. PubMed ID: 16766129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources.
    Heikkila RE
    Eur J Pharmacol; 1985 Oct; 117(1):131-3. PubMed ID: 3878793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.
    Ogawa N; Mizukawa K; Hirose Y; Kajita S; Ohara S; Watanabe Y
    Eur Neurol; 1987; 26 Suppl 1():16-23. PubMed ID: 2884111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.